We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Tops Q1 Earnings on Strong Revenues
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its first-quarter fiscal 2017 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings fell 10% on a year-over-year basis to $1.24 per share. It however managed to outpace the Zacks Consensus Estimate of $1.21.
Revenues: Revenues increased 14% on a year-over-year basis to $32.0 billion. It also managed to beat the Zacks Consensus Estimate of $31.2 billion.
Key Stats: Pharmaceutical revenues surged 14% to $28.8 billion while revenues from Medical segment increased 12% to $3.3 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices fell 0.74% in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Tops Q1 Earnings on Strong Revenues
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its first-quarter fiscal 2017 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
CARDINAL HEALTH Price and EPS Surprise
CARDINAL HEALTH Price and EPS Surprise | CARDINAL HEALTH Quote
Earnings: Cardinal Health’s adjusted earnings fell 10% on a year-over-year basis to $1.24 per share. It however managed to outpace the Zacks Consensus Estimate of $1.21.
Revenues: Revenues increased 14% on a year-over-year basis to $32.0 billion. It also managed to beat the Zacks Consensus Estimate of $31.2 billion.
Key Stats: Pharmaceutical revenues surged 14% to $28.8 billion while revenues from Medical segment increased 12% to $3.3 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices fell 0.74% in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>